Sagimet Biosciences Inc. gets a Buy rating as denifanstat targets MASH & acne; key Phase 3 catalysts and funding risks ahead.
The investment seeks to track the performance of the Russell 3000® Index that measures the investment return of the broad U.S. stock market. The advisor employs an indexing investment approach ...
The Carillon ClariVest International Stock Fund navigated a volatile quarter marked by Middle East conflict and AI-driven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results